



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C07D 498/04, 501/12	A1	(11) International Publication Number: WO 99/24441 (43) International Publication Date: 20 May 1999 (20.05.99)
(21) International Application Number: PCT/EP98/07224 (22) International Filing Date: 9 November 1998 (09.11.98) (30) Priority Data: 97203484.7 10 November 1997 (10.11.97) EP (71) Applicant (for all designated States except US): GIST-BROCADES B.V. [NL/NL]; Wateringseweg 1, P.O. Box 1, NL-2600 MA Delft (NL). (72) Inventors; and (75) Inventors/Applicants (for US only): HEITMANN, Herwardt [NL/NL]; Van Boisotring 31, NL-2722 AA Zoetermeer (NL). DE VROOM, Erik [NL/NL]; De Meij van Streef- erkstraat 65, NL-2313 JM Leiden (NL). ROY, Peter, Daniel [GB/NL]; Berkenlaan 47, NL-5941 EA Velden (NL). (74) Agents: VISSER-LUIRINK, Gesina et al.; Gist-Brocades B.V., Patents and Trademarks Dept. (994-0760), Water- ingseweg 1, P.O. Box 1, NL-2600 MA Delft (NL).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: CRYSTALLIZATION OF BETA-LACTAM COMPOUNDS (57) Abstract A process for the crystallization of β -lactam compounds involving simultaneous addition of a solution of said β -lactam compound and a titrant to a crystallization vessel. In case of zwitterionic β -lactam compounds, the pH-value is maintained between 2.5 and 7.5, preferably between the isoelectric point of said compound and 7.5 and at a temperature between 0 °C et 50 °C.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

CRYSTALLIZATION OF BETA-LACTAM COMPOUNDS

Field of the invention

5

The present invention relates to a new process for the crystallization of β -lactam compounds.

It is commonly accepted that the most economical approach for the isolation of compounds such as β -lactam antibiotics or their intermediates from their corresponding aqueous solutions is crystallization. For example in United States patent US 4,248,780 it has been described that the zwitterionic antibiotic ampicillin has been isolated from an aqueous solution containing the hydrochloride salt of ampicillin by adding gradually an aqueous base until the pH has reached a value of 4.5 to 5.3 followed by filtration of the ampicillin trihydrate crystals. The antibiotics amoxicillin, ampicillin and cephalexin are similarly obtained as described in European patent application EP 0011513 B. A major drawback of this crystallization procedure is the fact that it is carried out in a discontinuous way in batch processes and therefore difficult to control. Crystallization of unwanted by-products can thus occur at any stage of the crystallization procedure. Furthermore, as result of a discontinuous operation, often a wide range of crystal size distribution occurs. Another drawback of the crystallization process is that the crystalline products contain unacceptably high levels of hydrochloric acid salts.

Surprisingly it has been found that β -lactam antibiotics can be crystallized through a different process comprising simultaneous addition of a β -lactam compound and a corresponding titrant to a crystallization vessel. This method has not previously been described or suggested for β -lactams until now.

30

Summary of the invention

The present invention provides a process to prepare a crystalline β -lactam compound which comprises simultaneous addition of a solution of
5 said β -lactam compound and a corresponding titrant to a crystallization vessel to form a crystallization mixture and isolation of the crystalline β -lactam compound.

The β -lactam compounds are crystallized from a crystallization reaction
10 mixture or from a solution of said β -lactam compound in water or in a mixture of water and one or more organic solvents. The β -lactam compounds are for example penicillins, cephalosporins and clavams.

Examples of penicillins are amoxicillin, ampicillin, epicillin and
15 6 β -aminopenicillanic acid (6-APA).

Examples of cephalosporins are cefaclor, cefadroxil, cefprozil, cefetamet,
20 cefotaxim, cephalixin, cephaloglycin, cephradine, 7 β -aminocephalosporanic acid (7-ACA), 7 β -amino-3-chloro-3-(desacetoxymethyl)cephalosporanic acid (7-ACCA), 7 β -amino-3'-desacetoxymethylcephalosporanic acid (7-ADCA) and 7 β -amino-3'-desacetylcephalosporanic acid (7-ADAC).

Examples of clavams are for instance amine salts of clavams as t-butylamine clavulanate, t-octylamine clavulanate, bis(2-(dimethylamino)ethyl) ether
25 diclavulanate, N,N,N',N'-tetramethyl-1,2-diaminoethane mono-clavulanate or N,N,N',N'-tetramethyl-1,2-diaminoethane diclavulanate.

Detailed description of the invention

The crystallization process according to the present invention comprises
30 of optionally placing a small amount of solvent or crystallization reaction mixture of the β -lactam compound (0-10%) in a crystallization vessel followed

by simultaneous and separate addition of a solution of the said β -lactam compound and a titrant.

A solution of the β -lactam compound can be obtained:

by dissolving the β -lactam compound or a salt or an acidic addition salt thereof
5 in an acidic medium or

by dissolving the β -lactam in an alkaline salt form in water and/or an organic solvent, if necessary in alkaline medium or

by dissolving the β -lactam in the free acid form in an acidic medium in water and/or an organic solvent.

10 The corresponding titrant is defined in the present application as the acid or base which neutralises the β -lactam compound in the obtained solution and/or brings the β -lactam compound in the desired form. The titrant is optionally mixed with a solvent, and the concentration may vary between about 0.01 M to about 13 M when aqueous solutions are used, depending
15 upon the scale of the condensation reaction. The acid titrant is an inorganic acid, preferably anyone of the groups consisting of hydrochloric acid, sulphuric acid, nitric acid and phosphoric acid or an organic acid preferably formic acid or acetic acid. The base titrant is an inorganic base, preferably anyone of the groups consisting of sodium hydroxide, potassium hydroxide
20 and ammonium hydroxide or an organic base, preferably an amine, as for instance monoamine, preferably tertiary butylamine, tertiary octylamine, benzhydrylamine or a diamine, preferably N,N'-diisopropylethylenediamine, N,N,N',N'-tetramethyl-1,2- diaminoethane or bis(2-(dimethylamino)ethyl)ether.

In case the β -lactam compound is a zwitterionic antibiotic, the pH-value
25 is adjusted between 2.5 and 7.5, more specifically between the isoelectric point of the β -lactam compound and 7.5 by adding an acid or a base. Furthermore, seeding material may be added to the crystallization vessel before the addition of said compound and the titrant. The temperature of the crystalline vessel is preferably maintained between 0°C and 50°C and more
30 specifically between 0°C and 30°C. Subsequently, both the bulk of the solution of the β -lactam compound and a suitable titrant are added

simultaneously at such a ratio that the pH-value remains within the range as set above.

Accordingly, after filtration and drying crystalline products are obtained that contain no more than 1% of unwanted by-products such as acid salt of the same β -lactam compounds whereas known procedures give impurity levels of 3.5 to 9%. Another advantage of the present crystallization process is that it is easy to control as batch wise addition is avoided. Furthermore, as a result of continuous process operation the crystal size distribution can be minimized.

The present invention is particularly suitable for the preparation of β -lactam antibiotics and intermediates in the form of zwitterionic amino acid. Examples of said intermediates are 6 β -aminopenicillanic acid (6-APA), 7 β -aminocephalosporanic acid (7-ACA), 7 β -amino-3-chloro-3-(desacetoxymethyl)cephalosporanic acid (7-ACCA), 7 β -amino-3'-desacetoxycephalosporanic acid (7-ADCA), 7 β -amino-3'-desacetylcephalosporanic acid (7-ADAC), cephalosporin-C and salts thereof. These β -lactam compounds may be produced from the fermentation products penicillin-G or penicillin-V respectively by chemical means as described in Belgium patent BE 718824 and Recl. Trav. Pays-Bas 112, 66 (1993) or by an enzymatic conversion as described in European patents EP 283218, EP 322032 and EP 436355B, French patent application FR 2241557, United States patents US 4,141,790 and US 3,960,662 and International patent application WO 90/12110. 7-ADCA can be produced from 7-ACA as described in European patent EP 454478B, US patents US 3,304,236 and US 3,972,774. Furthermore, 7-ADCA, 7-ADAC and 7-ACA can be produced by fermentation followed by enzymatic conversion as described in European patent applications EP 532341 and EP 540210.

Examples of said zwitterionic antibiotics are amoxicillin, ampicillin, epicillin, cefaclor, cefadroxil, cefetamet, cefotaxim, cefprozil, cephalixin, cephaloglycin and cephradine. These antibiotics can be produced from β -lactam intermediates such as 6-APA, 7-ACA, 7-ACCA, 7-ADAC, 7-ADCA

and alpha-substituted phenylacetic acid derivatives, either chemically as described in Recl. Trav. Chim. Pays-Bas 112, 66 (1993) and references cited therein or enzymatically as described in International patent application WO 97/04086.

5 The process of crystallization of antibiotic compounds, according to the present invention, provides various advantages over the existing methods.

 In the first place better concordance results have been obtained. The concordance value which is related to the difference between titration with a strong acid and titration with a strong base has been defined according to the
10 United States Pharmacopeia, twenty-first revision, Official from 1 January 1985. A small concordance value stands for a constant quality product, for example, ampicillin trihydrate, isolated from crystallization of a solution containing ampicillin hydrochloride by adding a base has a concordance value of less than 1 mol %, while crystallization through a normal procedure of a
15 number of experiments has given a concordance value between 4 and 8 mol %. The β -lactam antibiotic compounds with a small concordance value, i.e. comprising for example lower amounts of acid salt of the corresponding β -lactam antibiotics, are suitable for pharmaceutical formulation purposes. The present invention provides also a better stability of the β -lactam antibiotic due
20 to short stay of the β -lactam antibiotic in solution during the crystallization process. Furthermore, a uniform particle size distribution provides better quality of the β -lactam antibiotic compounds.

 The preparation of amine clavam, for example amine clavulanate according to the present invention, does not require the adjustment of
25 pH-values because the clavulanic acid is not a zwitterionic compound. The crystallization of amine clavulanate, for instance bis(2-(dimethylamino)ethyl)ether diclavulanate through the addition of (dimethylamino)ethyl ether or N,N,N',N'-tetramethyl-1,2-diaminoethane diclavulanate or N,N,N',N'-tetramethyl-1,2-diaminoethane monoclavulanate
30 through the addition of N,N,N',N'-tetramethyl-1,2-diaminoethane as described in EP-647229B can advantageously take place by just adding clavulanic acid

and amine, preferably both in an organic solvent, simultaneously to a crystallization vessel. Suitable organic solvents for the clavulanic acid solution are ethyl acetate, methyl acetate, propyl acetate, n-butyl acetate, methyl ethyl ketone, methyl isobutyl ketone and mixtures thereof. The amine is
5 advantageously mixed with alcohols, nitriles, ketones, esters and mixture thereof. The present invention also covers the conversion of amine clavulanate prepared in this way into potassium clavulanate.

The invention will now be described with reference to the following examples, which are not to be constructed as being limiting the invention, but
10 are provided purely for illustrative purposes.

Example 1

**Preparation of crystalline 7 β -amino-3'-desacetoxycephalosporanic acid
15 from an enzymatic hydrolysis of 7 β -phenylacetamido-3'-desacetoxyceph-
3-em-4-carboxylic acid.**

Enzymatic conversion:

7 β -Phenylacetamido-3'-desacetoxycephalosporanic acid (80 g, 0.24
20 mole) and sodium metabisulfite (1 g, 0.005 moles) were suspended in water (0.62 l) in a three-necked round bottom flask equipped with a stirrer, a pH-electrode and a dropping funnel filled with ammonium hydroxide (25% in water, w/w).

With stirring, the temperature of the suspension was raised to 30°C. In
25 15 minutes, the pH was adjusted to 8.4 by the addition of ammonium hydroxide as a result of which the suspension dissolved into a clear solution. Immobilized *Alcaligenes faecalis* penicillin-G acylase, as described in International patent application WO 9704086 (30 g, weighed after filtering and washing the beads with water) was added, the total volume was adjusted
30 to 1.0 litre, and the mixture was stirred at 30°C for 4 hours at a stirring speed of approximately 50 rpm. During this process the pH was maintained at 8.4

by gradually adding ammonium hydroxide from the dropping funnel. The immobilized enzyme was removed by filtration and the beads were washed with water (0.1 l). The filtrate and washings were combined and further used in the next step.

5 Extraction

A two litre three-necked round bottom flask equipped with a stirrer, a pH-electrode and a dropping funnel filled with hydrochloric acid (36% in water, w/w) was charged with isobutanol (0.25 l) and hydrochloric acid (0.065 l). At 30°C, the 7-ADCA and phenylacetic acid containing solution
10 obtained after the enzymatic conversion was added in 15 minutes under stirring. During this process the pH of the mixture was maintained at 0.5 by gradually adding hydrochloric acid from the dropping funnel. The mixture was transferred to a separating funnel and the aqueous phase was isolated and extracted with isobutanol (0.25 l). Both isobutanol phases were combined and
15 extracted with water (0.1 l). Both aqueous phases were combined.

A second two litre three-necked round bottom flask equipped with a stirrer, a pH-electrode and a dropping funnel filled with ammonium hydroxide (25% in water, w/w) was charged with water (0.065 l). At 30°C, the combined 7-ADCA containing aqueous phases were added in 15 minutes
20 under stirring. During this process the pH of the mixture was maintained at 7.8 by gradually adding ammonium hydroxide from the dropping funnel. The mixture was transferred to a separating funnel, the aqueous phase was isolated to be used in the next step, and the isobutanol phase was discarded.

Crystallization

25 A two litre three-necked round bottom flask equipped with a stirrer, a pH-electrode and a dropping funnel filled with aqueous sulphuric acid (6N) was charged with water (0.065 l). At 30°C, the 7-ADCA containing aqueous phase obtained after extraction was added in 30 minutes under stirring. During this process the pH of the mixture was maintained at 5.1 by gradually
30 adding sulphuric acid from the dropping funnel. When addition was completed, the pH of the suspension was lowered to 3.6 by the addition of

sulphuric acid and the temperature was lowered to 2°C. Stirring was continued for 30 minutes.

Isolation

The 7-ADCA crystals obtained above were isolated by filtration using a glass sintered funnel and washed with water (0.25 l). The white 7-ADCA crystals were dried at 50°C until a constant weight of 45 g (purity 99%, 0.21 moles, yield 87.5%) was reached.

Example 2

Preparation of crystalline ampicillin trihydrate from an aqueous solution containing ampicillin hydrochloride by simultaneous addition of base etc.

A crystallization vessel containing cold water (0.3 l) and equipped with a stirrer, a pH-electrode and a dropping funnel filled with ammonium hydroxide (25% in water, w/w), was charged with an aqueous solution containing 15% (w/w) ampicillin hydrochloride (0.15 l). A few crystals of ampicillin trihydrate were added and after stirring for 5 minutes, an aqueous solution containing 15% (w/w) ampicillin hydrochloride (2.85 l) was added in 45 minutes under stirring and the pH of the reaction mixture was maintained at 5.5 by gradually adding ammonium hydroxide from the dropping funnel. When the addition was completed, the mixture was stirred for 5 minutes. The pH of the suspension was lowered to 4.9 by the addition of hydrochloric acid (2M). After lowering the temperature to 0°C, stirring was continued for 2 hours. The crystals were collected by filtration, washed with acetone and dried to give ampicillin trihydrate in a yield of 92%.

The concordance value of crystalline ampicillin trihydrate was less than 1 mol %.

Comparison with the preparation of crystalline ampicillin trihydrate by adding a base to a solution of ampicillin hydrochloride.

Ammonium hydroxide (25% in water, w/w) was added gradually to an aqueous solution containing 15% (w/w) ampicillin hydrochloride (0.15 l) under

stirring till the pH was raised from 1.5 to 5.1. At pH = 2.5, some crystalline ampicillin trihydrate were added as seed. The crystalline slurry was stored overnight at 0°C and, then, the crystals were collected by filtration, washed with acetone and dried to give ampicillin trihydrate.

5 The concordance value of the crystalline ampicillin trihydrate is 4-8 mol % after repetition of a number of experiments.

Example 3

10 **Crystallisation of bis(2-(dimethylamino)ethyl)ether clavulanate from a clavulanic acid solution by simultaneous addition of clavulanic acid and bis(2-(dimethylamino)ethyl)ether**

Ethanol (50 ml) was placed into a one litre three-necked round bottom flask fitted with a thermometer, two dropping funnels and a stirrer. The temperature was brought to 10°C and under stirring an impure solution of
15 clavulanic acid (400 ml; 32.9 g clavulanic acid/litre) in ethyl acetate and a solution of bis(2-(dimethylamino)ethyl)ether (13.5 g) in ethanol (230 ml) were added simultaneously during 15-20 minutes at 10-15°C. After the addition the mixture was stirred for one hour at 5°C. The crystals were filtered, washed
20 twice with ethyl acetate (40 ml) and dried under vacuum at room temperature. Bis(2-(dimethylamino)ethyl)ether diclavulanate (15.97 g; purity = 95%) in a yield of 80% was obtained.

Example 4

25

Crystallisation of bis(2-(dimethylamino)ethyl)ether clavulanate from a clavulanic acid solution by simultaneous addition of clavulanic acid and bis(2-(dimethylamino)ethyl)ether

The following experiment was carried out under nitrogen atmosphere. A
30 volume of 250 ml of dry ethyl acetate was added to an empty vessel. Then, in approximately 5 minutes under vigorous stirring simultaneously 2 vol-% of

1000 ml of a solution of clavulanic acid in ethyl acetate, with a concentration of ca 40 g/l clavulanic acid, and 2 vol-% of a solution of 22.9 grams of amine in 250 ml ethyl acetate are added. The temperature during addition was 37°C. After crystallisation the remaining 98 vol-% of both clavulanic acid
5 solution and amine solution were added in ratio in approximately 5 minutes. In the meantime, cooling was started to reach 18°C at the time the addition of the solutions was finished. Cooling was proceeded until 0 - 5°C and the crystal slurry was stirred at this temperature for one hour. The crystals were separated by filtration and washed twice with 100 ml ethyl acetate. The
10 crystals were dried under vacuum atmosphere at room temperature to yield 64.3 g of bis(2-dimethylamino)ethyl) ether diclavulanate. The purity of the crystals was 62.7% based on clavulanic acid and the yield was 99.5%.

CLAIMS

1. A process to prepare a crystalline β -lactam compound which comprises simultaneous addition of a solution of said β -lactam compound and
5 a corresponding titrant to a crystallization vessel to form a crystallization mixture and isolation of the crystalline β -lactam compound.

2. A process according to claim 1 wherein a small amount of solvent or crystallization mixture is present in the crystallization vessel before the
10 addition of the solution of the β -lactam compound and the titrant.

3. A process according to any one of the claims 1-2 wherein the crystallization vessel is provided with seeding crystals.

15 4. A process according to any one of the claims 1-3 wherein the temperature of the crystallization vessel is maintained between 0°C and 50°C.

5. A process for the crystallization of a zwitterionic β -lactam compound according to any one of the claims 1-4 wherein the pH-value is maintained
20 between 2.5 and 7.5.

6. A process according to claim 5 wherein the pH-value is maintained between the isoelectric point of said β -lactam compound and 7.5.

25 7. A process according to claims 1-6, which comprises the addition of an aqueous solution of the β -lactam compound.

8. A process according to claims 1-7, which comprises the addition of a solution of a β -lactam compound in a mixture of water and one or more
30 organic solvents.

9. A process according to claims 1-8 wherein the titrant is an inorganic or organic acid or an inorganic or organic base.

10. A process according to claim 9 wherein the inorganic acid is selected from the group consisting of hydrochloric acid, sulphuric acid, nitric acid and phosphoric acid or the organic acid is formic acid or acetic acid.

11. A process according to claim 9 wherein an inorganic base is selected from the group consisting of sodium hydroxide, potassium hydroxide and ammonium hydroxide or the organic base is a monoamine or diamine.

12. A process according to claim 11, wherein the monoamine is selected from the group consisting of tertiary butylamine, tertiary octylamine, benzhydrylamine or the diamine is selected from the group consisting of N,N'-diisopropylethylenediamine, N,N,N',N'-tetramethyl-1,2-diaminoethane and bis(2-(dimethylamino)ethyl)ether.

13. A process according to claims 1-12 wherein the β -lactam compound is chosen from the group consisting of amoxicillin, ampicillin, epicillin, cefaclor, cefadroxil, cefprozil, cefetamet, cefotaxim, cephalixin, cephaloglycin, cephradine, 6 β -aminopenicillanic acid (6-APA), 7 β -aminocephalosporanic acid (7-ACA), 7 β -amino-3-chloro-3-(desacetoxymethyl)cephalosporanic acid (7-ACCA), 7 β -amino-3'-desacetoxycephalosporanic acid (7-ADCA), 7 β -amino-3'-desacetylcephalosporanic acid (7-ADAC) and cephalosporin-C.

14. A process to prepare crystalline amine clavulanate according to anyone of the claims 1-3 which comprises simultaneous addition of a solution of clavulanic acid and an amine in an organic solvent and isolation of the crystalline amine clavulanate.

15. A process according to claim 14, wherein the solution of clavulanic acid is in ethyl acetate and the amine is bis(2-(dimethylamino)ethyl)ether in ethanol solution.

5 16. A process for the preparation of an alkali metal salt of clavulanic acid, which comprises the conversion of the amine clavulanate, prepared according to claim 14 or 15, to potassium clavulanate.

10 17. A process according to claim 16, which comprises the conversion of the amine clavulanate into potassium clavulanate by addition of potassium 2-ethylhexanoate.

15 18. Crystalline β -lactam zwitterionic compound with an impurity level of the acidic addition salt of the corresponding β -lactam compound of lower than 1% by weight.

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D498/04 C07D501/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,Y	WO 97 47301 A (SMITHKLINE BEECHAM CORP.) 18 December 1997 see claims 1-44	1-18
Y	DE 29 01 730 A (GLAXO GROUP LTD.) 19 July 1979 see claims 1-9	1-18
Y	DATABASE WPI Week 9541 Derwent Publications Ltd., London, GB; AN 95-319168 XP002092684 & SU 1 512 094 A (SECT. ANTIBIOTICS RES. INST.), 27 February 1995 see abstract	1-18
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

9 February 1999

Date of mailing of the international search report

18/02/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Herz, C

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4 456 753 A (D. J. O'BRIEN, JR.) 26 June 1984 see claims 1-4	1-18
A	US 3 498 979 A (H. A. CRISP ET AL.) 3 March 1970 see claims 1-18	1-18
A	EP 0 327 364 A (ELI LILLY AND CO.) 9 August 1989 see claims 1,2	1-18
A	EP 0 369 687 A (ELI LILLY AND CO.) 23 May 1990 see claims 1-6	1-18
A	DE 20 36 907 A (GLAXO LABORATORIES LTD.) 15 April 1971 see claims 1-8	1-18
A	EP 0 439 353 A (ELI LILLY AND CO.) 31 July 1991 see claims 1-6	1-18

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9747301	A	18-12-1997	AU 3392797 A	07-01-1998
DE 2901730	A	19-07-1979	CH 638218 A	15-09-1983
			FR 2414509 A	10-08-1979
			GB 2012270 A,B	25-07-1979
			JP 1461670 C	14-10-1988
			JP 54117492 A	12-09-1979
			JP 63008115 B	19-02-1988
			NL 7900356 A,B,	19-07-1979
			US 4298732 A	03-11-1981
US 4456753	A	26-06-1984	AT 24515 T	15-01-1987
			AU 541675 B	17-01-1985
			AU 2420984 A	16-08-1984
			CA 1190220 A	09-07-1985
			DK 51784 A,B,	08-08-1984
			EP 0118196 A	12-09-1984
			FI 840475 A,B,	08-08-1984
			GR 81694 A	12-12-1984
			HK 99687 A	31-12-1987
			IE 56752 B	04-12-1991
			JP 1918358 C	07-04-1995
			JP 6043429 B	08-06-1994
			JP 59148789 A	25-08-1984
			KE 3755 A	02-10-1987
			PT 78058 B	02-06-1986
			ZA 8400853 A	25-09-1985
US 3498979	A	03-03-1970	NONE	
EP 327364	A	09-08-1989	AU 615026 B	19-09-1991
			AU 2961989 A	10-08-1989
			CN 1034929 A	23-08-1989
			DK 49989 A	07-08-1989
			JP 2001489 A	05-01-1990
			PT 89612 A	04-10-1989
			SU 1750429 A	23-07-1992
EP 369687	A	23-05-1990	AT 136306 T	15-04-1996
			AU 614440 B	29-08-1991
			AU 4457289 A	31-05-1990
			CA 2002597 A	14-05-1990
			CN 1042711 A,B	06-06-1990
			DE 68926148 D	09-05-1996
			DE 68926148 T	19-09-1996
			DK 563689 A	15-05-1990
			ES 2085281 T	01-06-1996
			GR 3019677 T	31-07-1996
			IE 74167 B	02-07-1997
			IL 92270 A	21-10-1994
			JP 2180882 A	13-07-1990
			JP 2842640 B	06-01-1999
			MX 18317 A	01-11-1993
			PH 26103 A	06-02-1992
			PT 92270 A,B	31-05-1990
			RU 2002749 C	15-11-1993
			SU 1833387 A	07-08-1993
			RU 2028298 C	09-02-1995

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 369687 A		US 4977257 A	11-12-1990
DE 2036907 A	15-04-1971	CH 545317 A	31-01-1974
		FR 2060565 A	18-06-1971
		GB 1317159 A	16-05-1973
		NL 7010977 A	30-03-1971
		US 3676437 A	11-07-1972
EP 439353 A	31-07-1991	AU 631960 B	10-12-1992
		AU 6992391 A	01-08-1991
		CA 2034592 A	27-07-1991
		CN 1053611 A	07-08-1991
		DE 69118933 D	30-05-1996
		DE 69118933 T	02-10-1996
		ES 2087240 T	16-07-1996
		FI 910365 A	27-07-1991
		HU 208972 B	28-02-1994
		JP 4234880 A	24-08-1992
		MX 24247 A	01-11-1993
		PT 96531 A	15-10-1991
		SU 1825365 A	30-06-1993

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.